Oesophagus

'Practice-Changing' Data Expand Zanidatamab's Approval to Gastroesophageal Cancer

On 25 August 2026 the FDA approved zanidatamab (Ziihera) in the first-line treatment of unresectable locally advanced or metastatic HER2-positive gastric, gastro-oesophageal junction and oesophageal adenocarcinoma. In the registration trial HERIZON-GEA-01 (NCT05152147) the zanidatamab plus tislelizu…